Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Jun 27, 2017
Trading Halt
Jun 02, 2017
Investor presentation, 2 June 2017
May 31, 2017
Neuren announces grant of two new patents to 2032
May 29, 2017
Notice of Annual General Meeting/Proxy Form
May 08, 2017
Response to Appendix 4C Query
Apr 28, 2017
Appendix 4C - quarterly
Apr 28, 2017
Appendix 4G
Apr 28, 2017
Annual Report to shareholders
Apr 04, 2017
Neuren receives $1 million R&D Tax Incentive
Apr 03, 2017
Investor presentation, 3 April 2017
Previous
1
2
3
4
5
Next
